You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《業績》賽諾菲次季王牌消炎藥Dupixent銷售勝預期 上調全年銷售預測
阿思達克 07-31 15:21
法國藥業巨擘賽諾菲(Sanofi)公布次季業績,列賬銷售99.94億歐元符預期,按年升6%,以固定匯率計升10.1%,撇除單次項目後季度業務經營溢利24.61億歐元,遜預期的25.7億歐元。 公司解釋,研發成本上升及與合作夥伴再生元製藥(Regeneron)(REGN.US)更高利潤分享壓抑予季度利潤。 受集團王牌消炎藥Dupixent、疫苗及新療法需求強勁帶動,賽諾菲上調全年銷售指引,料銷售有高單位數增長,原先料以固定匯率計有中至高單位數增長。賽諾菲確認今年純利有低雙位數增長預測,但指預測已計及新收購業務的所有開支。公司早前完成對罕見免疫病療法開發商Blueprint Medicines的收購,涉最多95億美元。 Dupixent由公司與再生元合作開發,去年獲批新適應症,可用於慢性阻塞性肺疾病(COPD)。次季Dupixent銷售升21.1%至38.3億歐元,高於市場預期的37.4億歐元。 上季賽諾菲疫苗銷售以固定匯率計升10%至12.1億歐元,高於市場預期的11.4億歐元。 賽諾菲今日(31日)初段跌1.8%,報83.95歐元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account